CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 6 enrolled
Drug / intervention
indocyanine green (ICG) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02910726
NCT02910726Phase 3Completed
CompareCT.gov

Non-inferiority Study of Intra-operative Indocyanine Green Fluorescent Dye Versus Technetium Lymphoscintigraphy for Sentinel Lymph Node Biopsy in Pediatric Malignancies

Memorial Sloan Kettering Cancer Center·interventional·Posted Sep 22, 2016·Updated Oct 5, 2022

In Brief

A Phase 3 clinical trial evaluating Sentinel Lymph Node Biopsy and indocyanine green (ICG) for Pediatric Patients With Solid Tumors. Completed, enrolled 6 participants across 3 sites.

Detailed Summary

This study is being done in patients that have tumors to find out how well sentinel lymph nodes (SLNs) can be found with a special dye called indocyanine green (ICG).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPediatric Patients With Solid Tumors
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 22, 2016
Enrollment StartSep 13, 2016
Primary CompletionSep 2, 2022
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 9.8 years ago

Interventions

Sentinel Lymph Node Biopsyprocedure

indocyanine green (ICG)drug